Clinical trial Recruiting at 1 site Interventional Ages 18 to 55

Cognitive Remediation Therapy for improving cognitive and emotional skills in schizophrenia

Official title: A Randomized Controlled EEG-GSR Study on the Effects of Cognitive Remediation Therapy on Neurophysiological and Emotional Regulation Markers in Schizophrenia

Run by Beykoz University · NCT06936397 · Data updated 2026-11-12

This study tests if Cognitive Remediation Therapy can help people with schizophrenia improve their thinking and emotional skills over 12 weeks.

More Cognitive Dysfunction trials

Quick facts

Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment60 (estimated)
SponsorBeykoz University
Academic / other
Locations1 site (Istanbul)
StatusRecruiting
StartedMarch 15, 2025
Main results expectedAugust 15, 2025
Study endsOctober 15, 2025
Registry record updatedApril 20, 2025
Trial IDNCT06936397 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 18 to 55 diagnosed with schizophrenia who are clinically stable and able to provide informed consent.

Probably not a fit

Patients with current or past substance use disorders, significant neurological illnesses, or those with severe cognitive impairments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of Cognitive Remediation Therapy (CRT) on cognitive and emotional functioning in individuals with schizophrenia. It involves a randomized controlled design with 60 participants, including 30 diagnosed with schizophrenia and 30 healthy controls. Participants with schizophrenia will receive CRT over 12 weeks, focusing on enhancing attention, memory, and emotional regulation through structured exercises. The study will utilize EEG and GSR measurements to assess changes in brain activity and emotional responses before and after the intervention.

Why it matters

Potential benefit: If successful, this therapy could significantly enhance cognitive and emotional functioning in patients with schizophrenia, leading to improved quality of life.

How similar studies have gone: Previous studies have shown promising results for cognitive remediation therapies in schizophrenia, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria (Schizophrenia Group):

* Diagnosed with schizophrenia according to DSM-5 criteria
* Age between 18 and 55 years
* Clinically stable (no hospitalization or medication change within 1 month)
* Minimum primary school education
* Able to provide informed consent
* Right-handed (for EEG protocol consistency)

Inclusion Criteria (Healthy Control Group):

* No history of psychiatric or neurological disorders
* Age- and gender-matched to schizophrenia group
* No current medication affecting CNS
* Able to provide informed consent
* Right-handed

Exclusion Criteria (Both Groups):

* Current or past substance use disorder (within the past year)
* Comorbid neurological illness (e.g., epilepsy, traumatic brain injury)
* Current use of benzodiazepines or medications that significantly affect cognitive function
* Intellectual disability or MoCA score \< 20
* Visual or hearing impairments that could interfere with task performance
* Participation in a psychological intervention in the last 3 months

Where it's running

  • Beykoz University
    Istanbul, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.